Medicines not recommended for inclusion in the who essential medicines list: a retrospective observational study
Enrico Costa(Brigham and Women's Hospital), Lorenzo Moja(Istituti di Ricovero e Cura a Carattere Scientifico), Veronika J. Wirtz, Hubert G. M. Leufkens(Utrecht University), Benedikt Huttner(University Hospital of Geneva), Francesco Nonino(Evidence (Italy)), Nicola Magrini(Evidence (Italy)), Bernadette Cappello(World Health Organization), Hendrika A. van den Ham(Utrecht University), Vittorio Del Grosso(Università degli Studi del Piemonte Orientale “Amedeo Avogadro”), Armando A. Genazzani(Università degli Studi del Piemonte Orientale “Amedeo Avogadro”)
Cited by 2
Related Papers
The WHO Bacterial Priority Pathogens List 2024: a prioritisation study to guide research, development, and public health strategies against antimicrobial resistance
|The Lancet Infectious Diseases|2025|526
The <i>WHO AWaRe (Access, Watch, Reserve) antibiotic book</i> and prevention of antimicrobial resistance
|Bulletin of the World Health Organization|2023|276
WHO global research priorities for antimicrobial resistance in human health
|The Lancet Microbe|2024|183
Access to cancer medicines deemed essential by oncologists in 82 countries: an international, cross-sectional survey
|The Lancet Oncology|2021|170
Antidepressant prescribing in five European countries: application of common definitions to assess the prevalence, clinical observations, and methodological implications
|European Journal of Clinical Pharmacology|2014|162